Investigational drug · Phase 2
GB268
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer (Locally Advanced or Metastatic).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GB268"
First trial start
2026
Jul 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GB268", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer (Locally Advanced or Metastatic)
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "GB268" as an intervention, largest first.
- A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid TumorsNot yet recruiting
Genor Biopharma Co., Ltd.Industry
NCT06934616 · 330 participants (planned) · Start Apr 24, 2025 · Primary completion Mar 2027
Drug: GB268 · For: Solid Tumor Cancer
- GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)Recruiting
Eddingpharm (Zhuhai) Co., Ltd.Industry
NCT07738341 · 270 participants (planned) · Start Jul 28, 2026 · Primary completion Aug 1, 2029
Drug: GB268; Nab-Paclitaxel and 2 more · For: Breast Cancer (Locally Advanced or Metastatic)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Breast Cancer (Locally Advanced or Metastatic)
- Dual-target CAR-NK cellsEB-DT-CAR-NK, Essen Biotech Dual-Target CAR-NKPhase 25 trials
Beijing Biotech · HER2-positive Breast Cancer, Non-Small Cell Lung Cancer, Breast Cancer (Locally Advanced or Metastatic)
- BL0175Phase 21 trial
Shanghai Best-Link Bioscience, LLC · Breast Cancer (Locally Advanced or Metastatic)
- INV-6452Phase 21 trial
Shenzhen Ionova Life Sciences Co., Ltd. · Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.